Tag: Biotech and Pharma

Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an ‌older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product.

Eli Lilly  continued its acquisition spree on Monday as the world’s largest drugmaker agreed to pay roughly $2.9 billion in cash for a biotechnology company developing treatments for autoimmune diseases.

Moderna plans to raise $2 billion by selling convertible senior notes due 2032, with proceeds earmarked for its cancer vaccine business and debt repayment, the company said Thursday.

Abbott agreed to pay $670 million to resolve a lawsuit over its specialty formulas for premature infants as well as about 2,000 related claims.

An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option.

Coloplast shares climbed 3.5% on Tuesday, after the Danish medical device maker beat sales expectations in its fiscal third quarter, offsetting a miss on profit margins tied to reimbursement setbacks in its Biologics unit and currency headwinds.

AstraZeneca said Monday it is discontinuing a late-stage trial testing its drug volrustomig, combined with chemotherapy, in patients with metastatic non-small cell lung cancer.

Hims & Hers Health reported a net loss of $86.3 million in the second quarter of 2026, swinging from net income of $42.5 million in the same period a year earlier, even as revenue climbed 38% to $753.2 million.

Cardinal Health  reported fourth quarter EPS of $2.60, $0.19 better than the analyst estimate of $2.41. Revenue for the quarter came in at $63.7B versus the consensus estimate of $65.22B.

Shares of Doximity surged more than 80% in premarket trading Friday after the medical networking and telehealth platform missed analysts’ earnings target.

“Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors. This approval also reflects the ongoing potential of our mRNA platform,” Moderna CEO Stéphane Bancel said.

There are “no discussions” ongoing between AstraZeneca and ​Bristol Myers Squibb over a potential ‌deal, a senior source close to the matter told Reuters on Wednesday, quashing the ​prospect of a mooted mega merger ​between the drugmakers.

Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro surged again.

Pfizer reported second-quarter revenue of $15.03 billion and raised the midpoint of its full-year revenue guidance on Tuesday.

Merck topped analysts’ second-quarter targets across its top and bottom lines even as dealmaking costs from a recent acquisition weighed on results.

AstraZeneca’s shares fell as investors balked on Monday at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world’s biggest drugmakers with a combined value of nearly $400 billion.

AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales.

Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.

Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after strong sales of blood thinner Eliquis ​and newer medicines such as heart drug Camzyos and anemia treatment Reblozyl helped ‌second-quarter results top analysts’ estimates.

Drugmaker Johnson & Johnson has announced a $5.5bn agreement to end long-running US litigation involving tens of thousands of claims that talcum powder allegedly caused ovarian cancer.